ADIPOQ and myelofibrosis: In agreement with these data, we demonstrate here for the first time a reduction in the number of ADIPOQ positive BMAds in the presence of cancer metastasis and myeloproliferative neoplasia with grade-3 myelofibrosis, thus confirming that the modulation of the secretory activity of BMAT contributes to the changes in the marrow/serum levels of this adipokine in neoplastic conditions.